A 58-year-old woman with newly diagnosed Parkinson's disease (tremor-dominant, mild functional impairment) is started on treatment. After 2 weeks on a dopamine agonist monotherapy, she develops orthostatic hypotension, ankle edema, and mild hallucinations. What is the most appropriate next step?

Explanation

## Clinical Presentation Analysis The patient has developed **significant dopamine agonist intolerance** manifesting as: - **Orthostatic hypotension** (peripheral vasodilation) - **Ankle edema** (fluid retention) - **Hallucinations** (CNS dopaminergic overstimulation) These are clinically significant adverse effects that, taken together — especially hallucinations — indicate that the dopamine agonist is not well tolerated and should be discontinued. ## Why Discontinue the Dopamine Agonist? **Key Point:** Hallucinations are a neuropsychiatric adverse effect of dopamine agonists that represent a **relative contraindication to continuing** the agent, particularly in older patients. Unlike mild nausea or dizziness (which may resolve with dose reduction), hallucinations signal CNS dopaminergic overstimulation that is unlikely to resolve with simple dose reduction and may worsen. Combined with orthostatic hypotension and edema, the overall adverse effect burden mandates switching rather than dose reduction. **High-Yield:** Dopamine agonists (pramipexole, ropinirole, rotigotine) carry a significantly higher risk of neuropsychiatric side effects (hallucinations, impulse control disorders), orthostatic hypotension, and edema compared to levodopa — particularly in patients over 60. Current guidelines (AAN, Movement Disorder Society) recommend levodopa/carbidopa as the preferred initial therapy in older patients (>60 years) or those who develop intolerance to dopamine agonists. ## Rationale for Switching to Levodopa/Carbidopa | Agent | Mechanism | Tolerability in Older Patients | Notes | |-------|-----------|-------------------------------|-------| | Dopamine agonist | D2/D3 receptor agonism | Worse — higher neuropsychiatric/autonomic side effects | Avoid if hallucinations develop | | Levodopa/carbidopa | Dopamine precursor | Better tolerated overall | First-line in elderly; most effective symptomatic therapy | | MAO-B inhibitor | Blocks dopamine breakdown | Good, but modest efficacy | Not adequate monotherapy for moderate symptoms | | Anticholinergic | Blocks acetylcholine | Poor in elderly — cognitive/urinary side effects | Contraindicated in older patients | **Clinical Pearl:** Levodopa/carbidopa remains the **most effective symptomatic treatment** for Parkinson's disease. While dopamine agonists are sometimes preferred in younger patients (<60 years) to delay levodopa-related motor complications, in a 58-year-old patient who has already developed hallucinations and autonomic side effects on a dopamine agonist, the risk-benefit balance clearly favors switching to levodopa/carbidopa. The carbidopa component reduces peripheral conversion of levodopa, minimizing nausea and orthostatic hypotension. ## Why Not the Other Options? - **Reduce dopamine agonist dose + add MAO-B inhibitor (Option C):** Dose reduction is appropriate for mild, early side effects (e.g., nausea), but hallucinations are a neuropsychiatric red flag that warrants discontinuation of the dopamine agonist, not dose reduction. Adding an MAO-B inhibitor would not adequately address the hallucinations or provide sufficient symptomatic control. - **Continue agonist + fludrocortisone (Option A):** Treating the side effect (orthostatic hypotension) while continuing the offending agent is inappropriate when hallucinations are also present. Fludrocortisone is not first-line for PD-related orthostatic hypotension. - **Switch to anticholinergic monotherapy (Option D):** Anticholinergics (benztropine) are contraindicated in elderly patients due to cognitive side effects and are ineffective for bradykinesia. They are not appropriate monotherapy for Parkinson's disease. [cite: Harrison 21e Ch 428; KD Tripathi 8e Ch 12; AAN Practice Guidelines for Parkinson's Disease]